Zantac
In October 2019, a class-action lawsuit was filed against Sanofi for allegedly misleadingly marketing the over-the-counter heartburn medication Zantac as safe when, according to plaintiffs, the medicine contains dangerously high levels of the carcinogen N-nitrosodimethylamine (NDMA). (Rodriguez et al v. Sanofi U.S. LLC et al, Case No. 19-cv-9527, S. D. NY.)
Class-Action Tracker
The Latest
Lens.com
Don’t let this company blindside you with its deceptive pricing.
Los Angeles Rams: “Thursday”
The Los Angeles Rams kick off the NFL Draft with help from some old neighborhood friends.
On Shoes
Lawsuit pokes holes in company’s Swiss branding.
Junk Fees at JFK, LaGuardia and Newark Airports
Why are these airport vendors slyly charging consumers for “employee benefits”?
FTC Takes TruHeight’s Growth Claims Down a Few Pegs
Supplement maker agrees to pay $750K to settle deceptive health claims lawsuit.